Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12089620 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9ANPC1ALDH1A1CYP3A4 | |
| SCHEMBL12582215 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9ANPC1ALDH1A1CYP3A4 | |
| SCHEMBL18622508 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9ANPC1ALDH1A1CYP3A4 | |
| SCHEMBL26661473 | 0.89 | RAB9A (0.56) | SMN1; SMN2RAB9ANPC1ALDH1A1CYP3A4 | |
| SCHEMBL11593077 | 0.88 | RAB9A (0.54) | SMN1; SMN2RAB9ANPC1ALDH1A1CYP3A4 | |
| SCHEMBL11593080 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ANPC1ALDH1A1CYP3A4 | |
| SCHEMBL18657172 | 0.87 | RAB9A (0.50) | SMN1; SMN2RAB9ANPC1ALDH1A1CYP3A4 | |
| SCHEMBL874473 | 0.87 | ALDH1A1 (0.54) | SMN1; SMN2RAB9ANPC1ALDH1A1CYP3A4 | |
| SCHEMBL29588785 | 0.87 | ALDH1A1 (0.54) | SMN1; SMN2RAB9ANPC1ALDH1A1CYP3A4 | |
| SCHEMBL14733954 | 0.87 | NPC1 (0.53) | SMN1; SMN2RAB9ANPC1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322694-A1 | COMPOUND | SUMITOMO CHEMICAL CO., LTD (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| EP-2751076-B1 | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2018-04-25 | — | — | EP | disclosed |
| EP-2558445-B1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2017-03-22 | — | — | EP | disclosed |
| US-20170073452-A1 | POLYGLYOXYLATES, MANUFACTURE AND USE THEREOF | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2017-03-16 | — | — | US | disclosed |
| US-20160367091-A9 | Personal Care Compositions Comprising a Di-Amido Gellant and Methods of Using | THE PROCTER & GAMBLE COMPANY | 2016-12-22 | — | — | US | disclosed |
| US-9334465-B2 | Structuring using an external structurant and a cosmotrope | THE PROCTER & GAMBLE COMPANY (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334465-B2 | Structuring using an external structurant and a cosmotrope | THE PROCTER & GAMBLE COMPANY (US) | 2016-05-10 | — | — | US | disclosed |
| WO-2015168809-A1 | POLYGLYOXYLATES, MANUFACTURE AND USE THEREOF | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2015-11-12 | — | — | WO | disclosed |
| US-9102704-B2 | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines | SPIROGEN SARL (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20080265221-A1 | TEMPLATED SEMICONDUCTOR PARTICLES AND METHODS OF MAKING | 3M INNOVATIVE PROPERTIES COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-7413607-B2 | Templated semiconductor particles and methods of making | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080152911-A1 | TEMPLATED METAL PARTICLES AND METHODS OF MAKING | 3M INNOVATIVE PROPERTIES COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080090812-A1 | Pyrrolobenzodiazepine Therapeutic Agents Useful in the Treatment of Leukemias | SPIROGEN LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-7344583-B2 | Methods of making metal particles within cored dendrimers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2007136997-A2 | COLOR FORMING COMPOSITIONS AND ASSOCIATED METHODS | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070269737-A1 | Color forming compositions and associated methods | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2007-11-22 | — | — | US | disclosed |
| US-20070269737-A1 | Color forming compositions and associated methods | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2007-11-22 | — | — | US | disclosed |
| US-20070191309-A1 | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191309-A1 | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines | CBR3, CBR1, CYCS | SMN1; SMN2 3275/4885RAB9A 1751/4885NPC1 2018/4885 |
| US-20230322694-A1 | COMPOUND | RAD51, NR0B1, XRN2 | SMN1; SMN2 2344/4885RAB9A 862/4885NPC1 3269/4885 |
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | NGLY1, ELOVL6, ELOVL1 | SMN1; SMN2 3292/4885RAB9A 3356/4885NPC1 499/4885 |
| US-20170073452-A1 | POLYGLYOXYLATES, MANUFACTURE AND USE THEREOF | IDUA, IDE, PUF60 | SMN1; SMN2 3940/4885RAB9A 4177/4885NPC1 4482/4885 |
| US-20080090812-A1 | Pyrrolobenzodiazepine Therapeutic Agents Useful in the Treatment of Leukemias | BCL3, CBR3, BCL9 | SMN1; SMN2 1711/4885RAB9A 1537/4885NPC1 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.